Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT05713773 Completed - Obesity Clinical Trials

Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects

Start date: October 25, 2019
Phase: Phase 1
Study type: Interventional

This single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover study was performed to assess pharmacodynamics (PD) and pharmacokinetics (PK) of three new developed coated Glucose beads formulations (containing glucose (8 g) and caffeine), one coated Glucose beads formulation (containing glucose (8 g)) and one uncoated Glucose beads formulation (containing Glucose (8 g) and caffeine) after single-dose administration (fasting conditions) in 20 obese healthy subjects. After an overnight fasting of at least 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. At least 3 days wash-out period was kept between each treatment periods.

NCT ID: NCT05711719 Recruiting - Metabolic Syndrome Clinical Trials

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging.

NCT ID: NCT05705804 Recruiting - Dyslipidemias Clinical Trials

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

Start date: June 13, 2023
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with atherosclerotic cardiovascular disease with metabolic syndrome.

NCT ID: NCT05705141 Not yet recruiting - Chronic Hepatitis b Clinical Trials

The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B

Start date: April 2024
Phase:
Study type: Observational

Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, the rising incidence of metabolic syndrome (MetS) is another grim health burden. Combined MetS affects the metabolic function of hepatocytes, which are responsible for providing HBV replication. Antiviral therapy is an effective measure to reduce the risk of cirrhosis and liver cancer in patients with chronic CHB. Combined MetS may affect the antiviral efficacy in patients with CHB.This prospective observational study examines the differences in HBeAg serological conversion rates between HBeAg-positive CHB patients with and without MS who received first-line oral antivirals for 144 weeks.

NCT ID: NCT05705063 Not yet recruiting - Obesity Clinical Trials

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.

NCT ID: NCT05703438 Completed - Clinical trials for Metabolic Syndrome, Protection Against

The Effect of a Low-calorie Diet With Balanced Nutrition on Metabolic Syndrome

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

The study looked at how a nutritionally balanced low-calorie diet based on traditional Indonesian foods affected obese people's metabolic biomarkers. The traditional Indonesian foods presented here are Minangkabau cuisine. Body mass index, waist circumference, systolic and diastolic blood pressure, body fat mass percentage, fasting blood sugar levels, and lipid profiles are among the metabolic biomarkers measured. The provision of a balanced nutritionally low-calorie diet based on traditional Indonesian foods, according to the researchers, will have a significant effect on the metabolic biomarkers of obese people.

NCT ID: NCT05702437 Recruiting - Metabolic Syndrome Clinical Trials

Effect of MetS* on Cognitive Performance and Physical Activity (Metabolic Syndrome)

Start date: February 20, 2023
Phase:
Study type: Observational [Patient Registry]

Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple. It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases. The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant. The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components. H1:There is a relationship between the MetS and cognitive functions.

NCT ID: NCT05698381 Completed - Depression Clinical Trials

Daily Vinegar Ingestion and Metabolic Health

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if vinegar ingestion promotes beneficial changes to metabolic health parameters in healthy, overweight adults.

NCT ID: NCT05696808 Recruiting - Metabolic Syndrome Clinical Trials

Effect of Indian Hepatoprotective Diet in Reversibility of NAFLD

NAFLDNutrition
Start date: January 16, 2023
Phase: N/A
Study type: Interventional

The modality of lifestyle modification including low calorie diets along with normal protein and moderate physical activity is the safest standard medical treatment for NAFLD in general. There are many benefits of weight loss to the patients with NAFLD. Besides the improvement in the features of metabolic syndrome, weight loss with IHPD would certainly improve the overall vitality and well being of the patients. The results of study will help to delineate a protocolized care for the management of NAFLD with metabolic syndrome thus helping other patients also in the future.

NCT ID: NCT05689710 Recruiting - Metabolic Syndrome Clinical Trials

The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

Start date: December 23, 2022
Phase: N/A
Study type: Interventional

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis